Global High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Report 2024
Market Analysis and InsightsGlobal High Potency Active Pharmaceutical Ingredients (HPAPI) Market
The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) = 10µg/m3.
Due to the COVID-19 pandemic, the global High Potency Active Pharmaceutical Ingredients (HPAPI) market size is estimated to be worth US$ 20980 million in 2024 and is forecast to a readjusted size of US$ 32610 million by 2034 with a CAGR of 6.4% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Synthetic HPAPIs accounting for % of the High Potency Active Pharmaceutical Ingredients (HPAPI) global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Oncology segment is altered to an % CAGR throughout this forecast period.
The United States High Potency Active Pharmaceutical Ingredients (HPAPI) market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of High Potency Active Pharmaceutical Ingredients (HPAPI) include Alkermes, Cambrex, Dishman, Dr. Reddy’S, Lonza, Novasep, Thermo Fisher Scientific, Pfizer and Merck Kgaa, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Scope and Market Size
The global High Potency Active Pharmaceutical Ingredients (HPAPI) market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Synthetic HPAPIs
Biotech HPAPIs
Oncology
Hormonal
Glaucoma
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Alkermes
Cambrex
Dishman
Dr. Reddy’S
Lonza
Novasep
Thermo Fisher Scientific
Pfizer
Merck Kgaa
Tapi Teva
The drugs are classified as High Potent if its Occupational Exposure Limit (OELs) = 10µg/m3.
Due to the COVID-19 pandemic, the global High Potency Active Pharmaceutical Ingredients (HPAPI) market size is estimated to be worth US$ 20980 million in 2024 and is forecast to a readjusted size of US$ 32610 million by 2034 with a CAGR of 6.4% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Synthetic HPAPIs accounting for % of the High Potency Active Pharmaceutical Ingredients (HPAPI) global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Oncology segment is altered to an % CAGR throughout this forecast period.
The United States High Potency Active Pharmaceutical Ingredients (HPAPI) market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of High Potency Active Pharmaceutical Ingredients (HPAPI) include Alkermes, Cambrex, Dishman, Dr. Reddy’S, Lonza, Novasep, Thermo Fisher Scientific, Pfizer and Merck Kgaa, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global High Potency Active Pharmaceutical Ingredients (HPAPI) Scope and Market Size
The global High Potency Active Pharmaceutical Ingredients (HPAPI) market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Synthetic HPAPIs
Biotech HPAPIs
Segment by Application
Oncology
Hormonal
Glaucoma
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Alkermes
Cambrex
Dishman
Dr. Reddy’S
Lonza
Novasep
Thermo Fisher Scientific
Pfizer
Merck Kgaa
Tapi Teva
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices